| Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists J Kim, BT Aftab, JY Tang, D Kim, AH Lee, M Rezaee, J Kim, B Chen, ... Cancer cell 23 (1), 23-34, 2013 | 397 | 2013 |
| Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine S Turcan, AWM Fabius, A Borodovsky, A Pedraza, C Brennan, J Huse, ... Oncotarget 4 (10), 1729, 2013 | 278 | 2013 |
| 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft A Borodovsky, V Salmasi, S Turcan, AWM Fabius, GS Baia, CG Eberhart, ... Oncotarget 4 (10), 1737, 2013 | 194 | 2013 |
| Repurposing the antihelmintic mebendazole as a hedgehog inhibitor AR Larsen, RY Bai, JH Chung, A Borodovsky, CM Rudin, GJ Riggins, ... Molecular cancer therapeutics 14 (1), 3-13, 2015 | 89 | 2015 |
| Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade R Yang, S Elsaadi, K Misund, P Abdollahi, EN Vandsemb, SH Moen, ... Journal for immunotherapy of cancer 8 (1), 2020 | 82 | 2020 |
| Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2 A Borodovsky, MJ Seltzer, GJ Riggins Current opinion in oncology 24 (1), 83-89, 2012 | 72 | 2012 |
| Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide AS Yamashita, M da Costa Rosa, A Borodovsky, WT Festuccia, T Chan, ... Neuro-oncology 21 (2), 189-200, 2019 | 70 | 2019 |
| Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity A Borodovsky, CM Barbon, Y Wang, M Ye, L Prickett, D Chandra, J Shaw, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 69 | 2020 |
| Targeting adenosine A2A receptor antagonism for treatment of cancer M Congreve, GA Brown, A Borodovsky, ML Lamb Expert opinion on drug discovery 13 (11), 997-1003, 2018 | 61 | 2018 |
| Adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response B Sidders, P Zhang, K Goodwin, G O'Connor, DL Russell, A Borodovsky, ... Clinical Cancer Research 26 (9), 2176-2187, 2020 | 59 | 2020 |
| Generation of stable PDX derived cell lines using conditional reprogramming A Borodovsky, TJ McQuiston, D Stetson, A Ahmed, D Whitston, J Zhang, ... Molecular cancer 16, 1-7, 2017 | 41 | 2017 |
| Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant … AD Joshi, RC Botham, LJ Schlein, HS Roth, A Mangraviti, A Borodovsky, ... Oncotarget 8 (46), 80124, 2017 | 34 | 2017 |
| Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors T Hahn, M J Polanczyk, A Borodovsky, L V Ramanathapuram, ... Current pharmaceutical biotechnology 14 (3), 357-376, 2013 | 30 | 2013 |
| Development of a quantification method for adenosine in tumors by LC-MS/MS with dansyl chloride derivatization KJ Goodwin, E Gangl, U Sarkar, P Pop-Damkov, N Jones, A Borodovsky, ... Analytical biochemistry 568, 78-88, 2019 | 27 | 2019 |
| Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression A Borodovsky, Y Wang, M Ye, JC Shaw, KF Sachsenmeier, N Deng, ... Cancer Research 77 (13_Supplement), 5580-5580, 2017 | 27 | 2017 |
| A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres A Borodovsky, AK Meeker, EF Kirkness, Q Zhao, CG Eberhart, GL Gallia, ... Journal of neuro-oncology 121, 479-487, 2015 | 17 | 2015 |
| Inhibition of A2AR by AZD4635 induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models A Borodovsky, Y Wang, M Ye, JC Shaw, K Sachsenmeier, N Deng, ... Cancer Research 78 (13_Supplement), 3751-3751, 2018 | 16 | 2018 |
| Diverse, potent, and efficacious inhibitors that target the EED subunit of the polycomb repressive complex 2 methyltransferase SK Bagal, C Gregson, DH O’Donovan, KG Pike, A Bloecher, P Barton, ... Journal of Medicinal Chemistry 64 (23), 17146-17183, 2021 | 15 | 2021 |
| Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model V Voronova, K Peskov, Y Kosinsky, G Helmlinger, L Chu, A Borodovsky, ... Frontiers in Immunology 12, 617316, 2021 | 10 | 2021 |
| A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity RDO Jones, M Grondine, A Borodovsky, M San Martin, M DuPont, ... British Journal of Pharmacology 178 (3), 600-613, 2021 | 7 | 2021 |
charles eberhartProfessor of Pathology, Ophthalmology and Oncology, Johns Hopkins University School of MedicineVerified email at jhmi.edu
